MALVERN, Penn., May 24, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ( REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) Office of Drug Evaluation II regarding the New Drug Application (NDA) for IV meloxicam.
Recro Pharma Receives Complete Response Letter from the FDA
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться